This article is more than 5 years old. Information may no longer be current.
Combination therapy extends choroidal hypofluorescence compared with PDT alone
Retina. 2010;30(3):495-502.
Click Here to Manage Email Alerts
Combination therapy may extend the duration of choroidal hypofluorescence after photodynamic therapy, which may, in turn, reduce the need for re-treatment.
In a study of 242 eyes with subfoveal choroidal neovascularization caused by age-related macular degeneration, 92 eyes received PDT alone, 90 eyes received a combination with sub-Tenon injection of triamcinolone and 60 eyes received a combination with intravitreal Avastin (bevacizumab, Genentech). A brightness ratio of irradiated to nonirradiated areas of the retina was determined using indocyanine green angiograms at baseline and 3 months using a 256-grade gray scale and densitometry.
According to the study, irradiated to nonirradiated brightness ratio was 0.96 in patients who received PDT alone, 0.85 in patients who also received triamcinolone and 0.89 in patients who also received bevacizumab.
Overall, re-treatment with PDT was lower in patients with presence of hypofluorescence at 3 months. Of the eyes with hypofluorescence at 3 months, eight of 27 eyes (29.6%) in the PDT alone group required re-treatment at 3 months, whereas 10 of 57 eyes (17.5%) in the triamcinolone group and two of 29 eyes (6.9%) in the bevacizumab group required re-treatment.
Follow OSNSuperSite.com
on Twitter.